Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 1;28(4):620-7.
doi: 10.1200/JCO.2009.23.8485. Epub 2009 Dec 28.

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

Elizabeth A Chrischilles  1 , Jane F Pendergast, Katherine L Kahn, Robert B Wallace, Daniela C Moga, David P Harrington, Catarina I Kiefe, Jane C Weeks, Dee W West, S Yousuf Zafar, Robert H Fletcher
Affiliations

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer

Elizabeth A Chrischilles et al. J Clin Oncol. .

Erratum in

  • J Clin Oncol. 2010 May 1;28(13):2314

Abstract

Purpose: To describe chemotherapy use and adverse events (AEs) for advanced-stage, non-small-cell lung cancer (NSCLC) in community practice, including descriptions according to variation by age.

Methods: We interviewed patients with newly diagnosed, stages IIIB and IV NSCLC in the population-based cohort studied by the Cancer Care Outcomes Research and Surveillance Consortium, and we abstracted the patient medical records. AEs were medical events occurring during chemotherapy. Using logistic regression, we assessed the association between age and chemotherapy; with Poisson regression, we estimated event rate ratios and adjusted the analysis for age, sex, ethnicity, radiation therapy, stage, histology, and presence and grade of 27 comorbidities.

Results: Of 1,371 patients, 58% (95% CI, 55% to 61%) received chemotherapy and 35% (95% CI, 32% to 38%) had AEs. After adjustment, 72% (95% CI, 65% to 79%) of those younger than 55 years and 47% (95% CI, 42% to 52%) of those age 75 years and older received chemotherapy. Platinum-based therapies were less common in the older-age groups. Pretreatment medical event rates were 18.6% for patients younger than 55 years and were only 9.2% for those age 75 years and older (adjusted rate ratio, 0.49; 95% CI, 0.26 to 0.91). In contrast, older adults were more likely to have AEs during chemotherapy. The adjusted rate ratios compared with age younger than 55 years were 1.70 for 65- to 74-year-olds (95% CI, 1.19 to 2.43) and 1.34 for those age 75 years and older (95% CI, 0.90 to 2.00).

Conclusion: Older patients who received chemotherapy had fewer pretherapy events than younger patients and were less likely to receive platinum-based regimens. Nevertheless, older patients had more adverse events during chemotherapy, independent of comorbidity. Potential implicit trade-offs between symptom management and treatment toxicity should be made explicit and additionally studied.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Adjusted percent (and 95% CI) of patients with advanced non–small-cell lung cancer treated with chemotherapy (n = 798) who experienced medical events between diagnosis and treatment initiation by age on the CanCORS (Cancer Care Outcomes Research and Surveillance Consortium) study.
See this image and copyright information in PMC

Comment in

References

    1. Surveillance Epidemiology and End Results. http://www.seer.cancer.gov/faststats/
    1. Non–Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non–small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909. - PMC - PubMed
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92–98. - PubMed
    1. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non–small-cell lung cancer (NSCLC): Update of the alpha oncology trial (A1-99002L) J Clin Oncol. 2005;23:627s. abstr LBA7025.
    1. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non–small-cell lung cancer: Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6(suppl 1):4–7. - PubMed

Publication types

MeSH terms